Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,131.53 -7.73 -0.25%
FTSE 100 6,588.52 4.35 0.07%
DAX 9,311.95 -5.87 -0.06%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438



Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate
                                    E7438

PR Newswire

CAMBRIDGE, Mass., March 22, 2013

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a
clinical stage biopharmaceutical company creating innovative personalized
therapeutics for patients with genetically defined cancers, announced today
that it has received a Notice of Issuance from the U.S. Patent and Trademark
Office (USPTO) for its patent application entitled "ARYL-OR
HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088. The
USPTO granted claims covering the novel small molecule EZH2 inhibitor EPZ-6438
(E7438), a drug candidate for a genetically defined type of non-Hodgkin
lymphomas. The patent issuance  marks Epizyme's first claims covering this
chemical matter.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In
March 2011, the two companies announced a worldwide partnership to discover,
develop and commercialize therapeutics targeting EZH2, with Epizyme retaining
an option to co-commercialize, co-develop and share profits for this program
with Eisai in the United States.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized
therapeutics for patients with genetically defined cancers. Epizyme has built
a proprietary product platform that we use to create small molecule inhibitors
of a 96-member class of enzymes known as histone methyltransferases, or HMTs.
HMTs are part of the system of gene regulation, referred to as epigenetics,
that controls gene expression. Genetic alterations can result in changes to
the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme
has entered into therapeutic collaborations with Celgene, Eisai and GSK that
have provided it with approximately $120 million in non-equity funding through
December 31, 2012. 

For more information, visit http://www.epizyme.com.

SOURCE Epizyme

Website: http://www.epizyme.com
Contact: Megan Lustig, Spectrum, +1-202.955.6222 ext. 2586,
mlustig@spectrumscience.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement